The businessman said on Wednesday that the clinical trial would begin after the US Food and Drug Administration (FDA) authorizes the application submitted.
During the ‘Neuralink Show and Tell: Fall 2022’ event, Tycoon revealed that the first two human applications of his brain device would be to restore vision and recover muscle motility.
Similarly, the practitioner highlighted progress made during the past year in the development of interfaces and wireless brain devices, which have been successfully tested in primates. At the beginning of his presentation, he showed how the implant allowed a monkey to telepathically control a computer cursor to select letters on a keyboard and even play video games.
In this context, Musk assured that he is ready to test his technology in the human brain. “We want to be extremely careful and make sure it’s going to work well before we put the device in humans, but I think we’ve submitted most of our documentation to the FDA and we think maybe about six In the month we’ll be able to get our first Neuralink.” Transplanted into a person, he claimed.
Read also: Scotland warns of bird flu death to pink-footed geese
Neuralink’s short-term goal is to develop a chip that allows the brain to control complex electronic devices and, in another instance, to help people with paralysis recover motor function and treat brain diseases such as Parkinson’s, dementia or Alzheimer’s. allows. sight. In the long term, the goal is to create a neural network that allows the brain to merge with artificial intelligence.
However, the company’s plans to begin clinical trials have been delayed by nearly two years, putting it behind biotech competitor Synchron, which last July achieved a major milestone by transplanting a patient in the United States for the first time. reached. In addition to completing four protocols with humans in Australia.